STOCK TITAN

Aquestive Therapeutics, Inc. (AQST) Free Cash Flow by Year

AQST

Aquestive Therapeutics, Inc. recorded an outflow of $53.0M in free cash flow in fiscal year 2025. This represents a decrease of 47.5% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to an outflow of $45.9M in free cash flow. The table below carries 9 fiscal years, from 2017 to 2025, and the quarters Aquestive Therapeutics, Inc. has filed alongside them.

FY2025 annual
Free Cash Flow -$53.0M
YoY -47.5%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

AQST Free Cash Flow by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-K
Free Cash Flow-$45.9M-$53.0M-47.5%-$35.9M-387.0%-$7.4M+32.0%-$10.8M+68.0%-$33.9M+26.3%-$46.0M+24.5%-$60.9M-310.9%-$14.8M-494.4%$3.8M

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

AQST Free Cash Flow by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Free Cash Flow-$9.7M-20.3%-$14.9M+36.9%-$8.6M-31.5%-$12.9M-7.7%-$8.0M-13.9%-$23.5M-126.0%-$6.5M-31.2%-$12.0M-378.8%-$7.0M+19.4%-$10.4M-218.1%-$5.0M-159.1%-$2.5M-196.4%

What free cash flow means

Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.

More Aquestive Therapeutics, Inc. financials

Frequently Asked Questions

What was Aquestive Therapeutics, Inc.'s free cash flow in fiscal year 2025?

Aquestive Therapeutics, Inc. recorded an outflow of $53.0M in free cash flow in fiscal year 2025.

How fast is Aquestive Therapeutics, Inc.'s free cash flow growing?

Aquestive Therapeutics, Inc. (AQST) free cash flow fell by 47.5% year over year, from -$35.9M to -$53.0M in fiscal year 2025.

What is Aquestive Therapeutics, Inc.'s free cash flow over the last twelve months?

Aquestive Therapeutics, Inc. (AQST) reported an outflow of $45.9M in free cash flow over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 9 fiscal years this page covers, Aquestive Therapeutics, Inc. (AQST) free cash flow went from $3.8M in fiscal year 2017 to -$53.0M in fiscal year 2025.

Aquestive Therapeutics, Inc. (AQST) reported -$9.7M in free cash flow in Q2 2026. This represents a decrease of 20.3% from the same quarter a year earlier.

Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Aquestive Therapeutics, Inc. (AQST) reported on that line in every period on record.